GRAIL (GRAL) released third quarter and nine month results on November 4, 2026, giving investors fresh detail on sales momentum, revenue trends, and ongoing losses from continuing operations.
The stock has cooled in the very short term, with a 1 day share price return of down 4.5% and a 7 day share price return of down 4.6%. However, the 90 day share price return of 65.7% and 1 year total shareholder return of 45.5% indicate momentum that has been building into these latest GRAIL results.
Look beyond GRAIL's volatile quarter and see how other health-focused companies with stronger balance sheets and fundamentals compare with the curated list of solid balance sheet and fundamentals (24 results)
Bulls see GRAIL’s recent 90 day surge and rising sales as proof the story is intact. Bears point to ongoing heavy losses and volatility. Which side do the current valuation numbers lean toward next?
GRAIL closed at $115.89, while the analyst consensus Narrative on Simply Wall St points to a fair value of $132.11 and applies a 7.5% discount rate to its long term cash flows and earnings power.
The $110 million equity financing and commercialization collaboration with Samsung, along with GRAIL’s cash position of $788.7 million and runway into 2029, provides resources to scale operations and international distribution. This is likely to affect future earnings and cash burn.
See why 20 investors see GRAIL as 12% undervalued.
Result: Fair Value of $132.11 (UNDERVALUED)
Still, the GRAIL story could be tested if high quarterly losses persist or if future clinical and regulatory decisions limit reimbursement and test volumes.
Find out about the key risks to this GRAIL narrative.
The SWS DCF model points to a future cash flow value of $21.94 per share, well below GRAIL’s current $115.89 price. By that lens, the stock screens as expensive and raises the question of whether the multi cancer testing story is already more than fully priced in.
For readers who want to see how this cash flow view is built step by step, Look into how the SWS DCF model arrives at its fair value.
Mixed messages on GRAIL so far. If the balance between risks and rewards feels tight, consider acting quickly and review the data for yourself with 2 key rewards and 5 important warning signs.
If GRAIL has sharpened your thinking, now is the moment to widen your watchlist with a few focused stock ideas tailored to different priorities.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com